US FDA weighs regulation of cannabis compound CBD in foods, supplements: WSJ – SABC News

The US Food and Drug Administration (FDA) plans to make recommendations on how to regulate the use of the popular cannabis compound CBD in foods and supplements, the Wall Street Journal reported Tuesday, citing agency officials.

After weighing the evidence on the compound’s safety, the FDA will decide within months how to regulate legal cannabis, and whether that will require new agency rules or new legislation from Congress, according to the report.

Shares of US-listed cannabis companies fell between 5% and 9% in afternoon trading after the report.

Cannabidiol or CBD is a non-psychoactive compound derived from cannabis.

Cannabis products, with the exception of Jazz Pharmaceuticals Plc’s Epidiolex, are federally illegal in the United States, although some states allow their use.

The agency wants to know whether CBD can be safely eaten daily over a long period of time or during pregnancy amid concerns about future fertility, Patrick Cournoye, who heads the FDA’s office that develops the agency’s cannabis strategy, told the WSJ.

When asked for comment, the FDA referred Reuters to a statement from last year that said the agency was taking steps to improve regulatory pathways for the legal marketing of appropriate cannabis and cannabis-derived products.

Related posts

Leave a Comment